High-dose ascorbic acid supplements are associated with a significantly increased risk of kidney stone formation in men, according to a research letter published online Feb. 4 in JAMA Internal Medicine.
Compared with standard screening, alternative prostate-specific antigen screening strategies could maintain good prostate cancer detection rates while reducing overdiagnoses and unnecessary biopsies, according to research published in the Feb. 5 issue of the Annals of Internal Medicine.
Ravicti (glycerol phenylbutyrate) has been approved by the U.S. Food and Drug Administration to treat certain urea cycle disorders (UCDs) in people 2 years and older.
For men presenting with erectile dysfunction, treatment with the phosphodiesterase type-5 inhibitor tadalafil is associated with improvements in ejaculatory and orgasmic function, according to a study published in the February issue of BJU International.
Physicians do not order fewer imaging tests if they are aware of the costs, according to a study published online Jan. 2 in the Journal of the American College of Radiology.
In a two-year, observational follow-up study of the four-year REduction by DUtasteride of prostate Cancer Events clinical study, men demonstrated a low rate of new prostate cancer diagnoses, although those men who had been treated with the 5α-reductase inhibitor dutasteride exhibited twice as many prostate cancers compared with placebo-treated men, according to research published in the March issue of The Journal of Urology.
The drug Oxytrol has been approved by the U.S. Food and Drug Administration as the first over-the-counter treatment for women 18 and older with overactive bladder.
Communities instituting quality improvement initiatives for care transitions see significant declines in the rate of 30-day rehospitalizations and hospitalizations, according to a study published in the Jan. 23/30 issue of the Journal of the American Medical Association.
Physicians' practice styles related to informed decision-making for prostate-specific antigen screening are linked to their personal beliefs about screening, according to a study published in the January/February issue of the Annals of Family Medicine.
U.S. Food and Drug Administration approval of Botox (onabotulinumtoxinA) has been expanded to include adults with overactive bladder who don't respond to anticholinergics.